![JCM | Free Full-Text | Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia JCM | Free Full-Text | Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia](https://www.mdpi.com/jcm/jcm-11-05828/article_deploy/html/images/jcm-11-05828-g001.png)
JCM | Free Full-Text | Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
![PDF] The role of aldosterone receptor antagonists in the management of heart failure: An update | Semantic Scholar PDF] The role of aldosterone receptor antagonists in the management of heart failure: An update | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/18579cba6f8135b6c5e499b814797ac583649574/5-Table1-1.png)
PDF] The role of aldosterone receptor antagonists in the management of heart failure: An update | Semantic Scholar
![Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta- Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension | Hypertension Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta- Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension | Hypertension](https://www.ahajournals.org/cms/asset/5cb1bf16-c840-458e-b641-20649bc315f3/hypertensionaha.122.19280.fig02.jpg)
Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta- Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension | Hypertension
![Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials | Heart Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials | Heart](https://heart.bmj.com/content/heartjnl/98/23/1693/F1.large.jpg)
Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials | Heart
![Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases | Hypertension Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases | Hypertension](https://www.ahajournals.org/cms/asset/22815da2-79d6-43f5-9499-26410ed7a27e/257fig01.jpeg)
Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases | Hypertension
![Frontiers | Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism Frontiers | Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism](https://www.frontiersin.org/files/Articles/625457/fendo-12-625457-HTML/image_m/fendo-12-625457-g001.jpg)
Frontiers | Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
![Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis - Hu - 2013 - British Journal of Clinical Pharmacology - Wiley Online Library Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis - Hu - 2013 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/acfc3b62-baa3-4b1a-8623-036cc89580b2/bcp12012-fig-0002-m.jpg)
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis - Hu - 2013 - British Journal of Clinical Pharmacology - Wiley Online Library
![Clinical use of aldosterone antagonists for slowing progression of chronic kidney disease: From the physiological basis to clinical application | Boletín Médico del Hospital Infantil de México (English Edition) Clinical use of aldosterone antagonists for slowing progression of chronic kidney disease: From the physiological basis to clinical application | Boletín Médico del Hospital Infantil de México (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/X2444340914395319:201v71n03-90339531fig1.jpg?idApp=UINPBA00004N)
Clinical use of aldosterone antagonists for slowing progression of chronic kidney disease: From the physiological basis to clinical application | Boletín Médico del Hospital Infantil de México (English Edition)
![Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial - The Lancet Diabetes & Endocrinology Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/a8db749c-056f-46fe-979d-b5aa50c77084/gr1.gif)
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial - The Lancet Diabetes & Endocrinology
![陳田文 on Twitter: "Comparison of aldosterone antagonist. #Spironolactone and #eplerenone. https://t.co/V9WRin3R0L" / Twitter 陳田文 on Twitter: "Comparison of aldosterone antagonist. #Spironolactone and #eplerenone. https://t.co/V9WRin3R0L" / Twitter](https://pbs.twimg.com/media/FDzKtE3acAAyBQF.jpg)